ImmuPharma PLC
IMM
Company Profile
Business description
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus, a life-threatening autoimmune disease, and other candidates are P140 CIDP and BioAMB Fungal infections.
Contact
One Bartholomew Close
LondonEC1A 7BL
GBRT: +44 2072062650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
Is the market still overlooking Alibaba’s AI potential?
Despite a 40% share price rally this year, investors could still be underestimating Alibaba’s cloud growth prospects.
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.10 | 46.00 | 0.51% |
| CAC 40 | 7,870.34 | 65.37 | 0.84% |
| DAX 40 | 24,377.50 | 191.91 | 0.79% |
| Dow JONES (US) | 44,851.22 | 71.05 | -0.16% |
| FTSE 100 | 9,177.24 | 12.01 | 0.13% |
| HKSE | 25,519.32 | 94.35 | -0.37% |
| NASDAQ | 21,703.20 | 9.94 | -0.05% |
| Nikkei 225 | 42,649.26 | 625.41 | -1.45% |
| NZX 50 Index | 12,834.08 | 67.54 | 0.53% |
| S&P 500 | 6,462.81 | 3.77 | -0.06% |
| S&P/ASX 200 | 8,873.80 | 46.70 | 0.53% |
| SSE Composite Index | 3,666.44 | 17.02 | -0.46% |